Advanced non-small cell lung carcinoma: The emerging role of docetaxel

Investigational New Drugs

Volumn 18, Issue 1, 2000, Pages 17-28

  Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Combined modality; Docetaxel; NSCLC; Systemic therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; NAVELBINE;

ADVANCED CANCER; ANEMIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; MUCOSA INFLAMMATION; MYALGIA; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; HUMANS; LUNG NEOPLASMS; PACLITAXEL; SALVAGE THERAPY; TAXOIDS;

EID: 0034064906     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006313927411     Document Type: Review

References (98)

1. Bonomi PD, Kim K, Chang A, et al: Phase III trial comparing etoposide-cisplatin versus taxol with cisplatin/G-CSF versus cisplatin in advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 15: A1145, 1996
2. LeChevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced NSCLC: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994
3. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized phase III trial of cisplatin vs. cisplatin plus navelbine in treatment of advanced non-small cell lung cancer: report of a Southwest Oncology Group study (abstract). Proc Am Soc Clin Oncol 15: A1110, 1996
4. Sandler A, Nemunaitis J, Denham C, Cormier Y, von Pawel J, Niyikiza C, Nguyen B, Einhorn L: Phase III study of cisplatin with or without gemcitabine in patients with advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 17: A1747, 1998
5. Ringel I, Horwitz SE: Studies with RP 56976 (Taxotere): A semi-synthetic analog of taxol. J Natl Cancer Inst 83: 288-291, 1991
6. Trudeau M: Docetaxel (Taxotere): A review of its pharmacology and clinical activity. Can J Oncol 6(1): 443-457, 1996
7. Bissery MC: Preclinical pharmacology of docetaxel. Eur J Cancer 31A (suppl 4): 1-6, 1995
8. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P: Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992-998, 1991
9. Rowinsky EK, Donehower RC: The clinical pharmacology and use of the antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52: 35-84, 1991
10. Bissery MC, Guenard D, Gueritte-Coegelein F, Lavelle F: Experimental antitumour activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991
11. Bissery MC, Bourzat JD, Commercon A, et al: Isolation, identification, synthesis and biological activities of docetaxel metabolites. 207th American Chemical Society National Meetings, 13-17 March 1994, San Diego, Calif, abstra MEDI 144
12. Hennequin C, Giocanti N, Faradon V: S-phase specificity of cell killing by docetaxel in synchronized HeLa cells. Br J Cancer 71: 1194-1198, 1995
13. Gumerlock PH, Mack PC, Luw SM, et al: Molecular mechanisms of response to cell cycle modulating agents in non-small cell lung carcinoma (NSCLC) (abstract). Proc Am Assoc Cancer Res 39: 610, 1998
14. Haldar S, Basu A, Croce C: Eel-2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997
15. Aapro M, Bruno R: Early clinical studies with docetaxel. Eur J Cancer 31A (Suppl 4): 4-10, 1995
16. Riou JF, Petitgenet O, Combeau C, Lavelle F: Cellular uptake and efflux of docetaxel (Taxotere) and Paclitaxel (Taxol) in P388 cell line (abstract). Proc Am Assoc Cancer Res 35: 385, 1994
17. Riou JF, Petitgenet O, Aynie I, Lavelle F: Establishment and characterization of docetaxel (Taxotere) resistant human breast carcinoma (Gale 18/TXT) and murine leukemic (P388/TXT) cell lines (abstract). Proc Am Assoc Cancer Res 35: 339, 1994
18. Xtra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042, 1993
19. Burris H, Irvin R, Kuhn J, et al: Phase I clinical trial of Taxotere administered as either a 20-hour or 6-hour intravenous infusion. J Clin Oncol 11: 950-958, 1993
20. Bissett D, Setanoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523-527, 1993
21. Pazdur R, Newman RA, Newman BM, et al: Phase I trial of Taxotere: Five-day schedule. J Natl Cancer Inst 84(23): 1781-1788, 1992
22. Tomiak E, Piccart M, Kerger S, et al: Phase I study of docetaxel administered as i-hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467, 1994
23. Pazdur R, Kudelka AP, Kavanagh JJ: Phase I studies of docetaxel (Taxotere) and selected phase II studies. Cancer Invest 12 (Suppl 1): 33-35, 1993
24. Piccart MJ, Klijn J, Paridaens R, et al: Steroids do reduce the severity and delay the onset of docetaxel induced fluid retention: Final results of a randomized trial of the EORTC Investigational Drug Branch for Breast Cancer (abstract). Eur J Cancer 31A (Suppl 5): 75, 1995
25. Leonard RC, O'Brien M, Barrett-Lee P, et al: A prospective analysis of 390 advanced breast cancer patients treated with Taxotere throughout the UK (abstract). Ann Oncol 7 (Suppl 5): 19, 1996
26. Tomiak E, Piccart MJ, Kerger J, et al: Phase I study of Taxotere (RP 56976, NSC 628503) administered as a one hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467, 1993
27. Eisenhauer EA, Lu F, Muldal A, et al: Predictors and treatment of docetaxel toxic effects. Ann Oncol S (Suppl 5): 506a, 1994
28. Fossella FB, Lee JS, Murphy WK, et al: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer. J Clin Oncol 12: 1238-1244, 1994
29. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small cell lung cancer: A phase II trial of the EORTC Early Clinical Trials Group. Br J Cancer 70: 384-387, 1994
30. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12: 1232-1237, 1994
31. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small-cell lung cancer. Cancer 75: 968-972, 1995
32. Kudo S, Hino M, Fukita A, et al: Late phase II clinical study of RP 56976 (docetaxel) in patients with non-small-cell lung cancer. Jpn J Cancer Chemother 21: 2617-2623, 1994
33. Burris H, Eckardt J, Fields S, et al: Phase II trial of taxotere in patients with non-small cell lung cancer (abstract 1116). Proc Am Clin Oncol 12: 335, 1993
34. Kawahara M, Furuse K, Watanabe K, et al: Phase II studies of docetaxel in patients with non-small cell lung cancer (NSCLC) (abstract). Ann Oncol S (Suppl 8): 148, 1994
35. Saarinen A, Jekunen A, Halme M, Pyrohonen S, Tamminen K, Boyer R, Roubille N, Mattson K: A phase II trial of docetaxel in advanced non-small cell lung cancer. Anti-Cancer Drugs 7(8): 890-892, 1996
36. Kunitoh H, Watanabe, Onoshi T, Furuse K, Niitani A, Taguchi T: Phase II trial of docetaxel in previously untreated advanced non-small cell lung cancer: A Japanese cooperative study. J Clin Oncol 14(5): 1649-1655, 1996
37. Robinet G, Kleisbauer JP, Thomas P, Perol M, Caries P, Paillotin D, Lena H, Poirier R, Clouet P, Lenseigne S, Soares JA: Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC (abstract 1726). Proc Am Soc Clin Oncol 16: 480a, 1997
38. Kath R, Blumenstengel K, Fricke HJ: Preliminary report of chemotherapy results with docetaxel in advanced non-small cell lung cancer (abstract 473). Ann Oncol 7 (suppl 5): 100, 1996. 21st Congress of the European Society for Medical Oncology (ESMO) Vicuna 1-5/11/96
39. Latreille J, Laberge F, Gelman K, Hirsch V, Maksymiuk A, Shepherd F, Delorme F: Docetaxel has moderate activity in patients with non-small cell lung cancer (abstract 142). 6th International Congress on Anti-Cancer Treatment, Paris 6-9/2/96, 76
40. Lire-Puerto V, Zepeda G, Mohar A, Gallardo D, De La Garza J, Silva A: Phase II trial of taxotere (docetaxel) in advanced non-small cell lung cancer (abstract 1136). Proc Am Soc Clin Oncol 14: 382, 1995
41. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 13: 645-651, 1995
42. Fossella FV, Lee JS, Berille J, et al: Summary of phase II data of docetaxel (Taxotere). An active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 22 (Suppl 4): 22-29, 1995
43. Alexopoulos K, Kouroussis C, Androulakis N, Papadakis E, Vaslamatzis M, Kakolyris S. et al: Docetaxel and granulocyte colony stimulating factor in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A multicenter phase II trial. Cancer Chemother Pharmacol 43 (Suppl 3): 257-262, 1999
44. Gandara D, Vokes E, Green M, Bonomi P, DeVore R, Comis R, Carbons D, Karp D, Belani C: Docetaxel (Taxotere) in plaintum-treated non-small cell lung cancer: confirmation of prolonged survival in a multi-center trial (abstract 1632). Proc Am Soc Clin Oncol 16: 454a, 1997
45. 2) versus vinorelbine or ifosfamide in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 18: 1776, 1999
46. Shepherd F, Ramlau R, Mattson K, Cressot L, O'Rourke M, Vincent M, Burbees M, Levitan W, Bergman B, Kraszko P, Baez L, Lynch T, Rudd R, Berille J, Rim Y, Coughlin S, Gralla R: Randomized study of taxotere vs. best supportive care in NSCLC patients previously treated with platinum based chemotherapy (abstract). Proc Am Soc Clin Oncol 18: A1794, 1999
47. Cole JT, Gralla RJ, Marques CB, Rittenberg CN: Phase I-II study of cisplatin+docetaxel (Taxotere) in non-small cell lung cancer (abstract 1087). Proc Am Soc Clin Oncol 14: 357, 1995
48. Verweij J, Planting AST, Vanderburg MEL, et al: A phase I study of docetaxel and cisplatin in patients with solid tumours (abstract 504). Proc 8th NCI-EORTC New Drugs Symposium 201, 1994
49. Pronk LC, Stoter G, Verweij J: Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side effects. Cancer Treat Rev 21: 463-478, 1995
50. Pronk LC, Schellens JHM, Planting ASTH, et al: A phase I and pharmacological study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15: 1071-1079, 1997
51. Zalcberg J, Bishop JF, Millward MJ, et al: Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer(abstract). Proc Am Soc Clin Oncol 14: 351, 1995
52. Millward MJ, Zalcberg J, Bishop JF, et al: Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small cell lung cancer. J Clin Oncol 15: 750-758, 1996
53. LeChevalier T, Monnier A, Douillard JY, et al: Docetaxel plus cisplatin: an active and well tolerated combination in patients with advanced non-small cell lung cancer. Eur J Cancer 34(13): 2032-2036, 1998
54. Androulakis N, Dimopoulos AM, Kourousis C, Kakolyris S, Papadakis E, Apostolopoulou F, Papadimitriou F, Vossos A, Aggelidon M, Heres P, Tzannes S, Souklakos J, Hodzidaki D, Georgoulias Y: First-line treatment of advanced non-small cell lung cancer (NSCLC) with docetaxel and cisplatin: A multicenter phase II study (abstract 1655). Proc Am Soc Clin Oncol 16: 461a, 1997
55. Douillard JY, Monnier A, Ibrahim N, et al: Preliminary report of a phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC) (abstract 1096). Eur J Cancer 31A (Suppl 5): 228-229, 1995
56. Belani C, Bonomi P, Dobbs T, et al: Multicenter phase H trial of docetaxel and cisplatin combination in patients with non-small cell lung cancer (abstract 1660). Proc Am Soc Clin Oncol 16: 462a, 1997
57. Mattson K, Vansteenkiste J, Saarinen A, Bargetzi M, Fillet G, Teixeira E, Gatzemeier U, Bereille J, Bougon N, Jekunen A: Phase II study of docetaxel alternating with cisplatin for advanced NSCLC - preliminary report of European multi-centre trial (abstract). Proc Am Soc Clin Oncol 16: A1707, 1997
58. Viallet J, LeBerge F, Martins H, et al: Docetaxel alternating with cisplatin and vinorelbine: Early evidence of additive activity in a phase II trial of non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 15: 375, 1996
59. Orcel B, Antoine EC, Benhammouda A, et al: Sequential administration of docetaxel followed by cisplatin-vindesine in chemotherapy naïve patients with locally advanced or metastatic non-small cell lung cancer (abstract 1718). Proc Am Soc Clin Oncol 16: 477a, 1997
60. Calvert A, Harland SJ, Newell DR, et al: Early clinical studies with cis-diammine-1,1 cyclobutane-decarboxylate-platinum II. Cancer Chemother Pharmacol 9: 140-147, 1982
61. Bonomi P, Finkelstein D, Ruckdeschel J, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 7: 1602, 1989
62. Belani C, Hadeed V, Ramanathan, et al: Docetaxel and carboplatin: a phase I and pharmacokinetic trial for advanced non-hematologic malignancies (abstract 771). Proc Am Soc Clin Oncol 16: 220a, 1997
63. Langer C, McAleer C, Millenson M, et al: Phase I evaluation of docetaxel (D) and carboplatin (C) in advanced malignancy: stratification of patient cohorts based on prior treatment (TX) status yields useful results (abstract 787). Proc Am Soc Clin Oncol 17: 204a, 1998
64. Giannakakis T, Papadauris S, Zivas N, et al. A phase I/II study of docetaxel and carboplatin as 1st line chemotherapy in advanced non-small cell lung cancer (abstract 1870). Proc Am Soc Clin Oncol 17: 486a, 1998
65. Schütte W. Phase II trial of docetaxel and carboplatin in the treatment of advanced non-small cell lung cancer, fur J Cancer 33, 1997
66. Capozzoli MJB, Belani CP, Einzig A, Bonomi P, Dobbs T, Kozak C, Cohen LJ: Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer (abstract 1845). Proc Am Soc Clin Oncol 17: 479a, 1998
67. Early E, Miller VA, Grant SC, et al: Phase I/II trial of docetaxel and vinorelbine with filgrastim in patients with advanced non-small cell lung cancer (abstract 439P). Ann Oncol 1996; 7(suppl 5): 92, 1996
68. King LM, Kris M, Grand S, Ng K, Heelan R, Pizzo B, Perez W, Miller V: Phase II trial of dose dense docetaxel plus vinorelbine with prophylactic filgrastim in advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 18: A1775, 1999
69. Aoe K, Ueoka H, Kiura K, et al: Synergistic effect of docetaxel and vinorelbine against the in vitro growth of a human small cell lung cancer line (abstract 2560). Proc Am Assoc Cancer Res 37: 375, 1996
70. Hino M, Kobayashi K, Hayashihara K, et al.: In vitro combination effect of docetaxel (RP 56976) with vinca alkaloids on cancer cell line (abstract 1780). Proc Am Assoc Cancer Res 36: 299, 1995
71. Bissery MC, Azli N, Fumoleau P: Docetaxel in combination with vinorelbine: Preclinical clinical correlation (abstract 1550). Proc Am Assoc Cancer Res 15: 487, 1996
72. Monnier A, Riviere A, Douillard JY, et al: Phase II study of docetaxel (Taxotere) and vinorelbine in chemotherapy naïve patients with advanced non-small cell lung cancer (NSCLC) (abstract 1129). Proc Am Soc Clin Oncol 15: 378, 1996
73. Trillet-Lenoir V, Monnier A, Douillard JY, et al: Interim results of a phase II study of docetaxel (Taxotere) and vinorelbine in chemotherapy naïve patients with advanced non-small cell lung carcinoma. Ann Oncol 7 (Suppl 5): 95, 1996
74. Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Papadakis E, et al.: Docetaxel and vinorelbine in the treatment of non-small cell lung cancer. Semin Oncol 24(4 suppl 14): S14, 9-14, 1997
75. Kourousis, C, Androulakis N, Kakolyris S, et al: First-line treatment of non-small cell lung carcinoma (NSCLC) with docetaxel and vinorelbine: A phase II study. Cancer 83(10): 2083-2090, 1998
76. Schiller JH, Larson M, Pharo L: Phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 16: A1703, 1997
77. Georgoulias V, Kourousis C, Bouros D, Kourousis C, Chatzakis K, Papadakis M, et al: Combination chemotherapy with docetaxel, vinorelbine and cisplatin as first line treatment of advanced non-small cell lung cancer: A multi-center phase II study of the Greek Cooperative Group for Lung cancer. Lung Cancer 21 (Suppl 3): 213-220, 1998
78. Plunket W, Huang P, Searcy CE, et al: Gemcitabine: Preclinical pharmacology and mechanisms of action. Semin Oncol 23 (Suppl 10): 3-15, 1996
79. Garland LL, Wagner H, Shaw GS, Williams CC, Antonia S, Khoor A, Meulemans LM, Nimmons KA, Ruckdeschel J: Phase I dose escalation study of constant rate infusion gemcitabine in combination with taxotere in advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 17: A1864, 1998
80. Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K, Nicol S. Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16(12): 3866-3873, 1998
81. Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Dimopoulos MA, Papadakis E, et al: Front-line treatment of advanced non-small cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial. J Clin Oncol 17: 914-920, 1999
82. Schrijvers D, Pronk L, Schellens J, et al: A phase I and pharmacokinetic study of docetaxel and ifosfamide in patients with advanced solid tumors (abstract). Ann Oncol 7 (Suppl 5): 125, 1996
83. Manegold C, Drings P: Phase I study of docetaxel in combination with ifosfamide in patients with metastatic or unresectable locally advanced NSCLC. Rhône-Poulenc Rorer GmbH, Clinical Research: Study code AN 95025, Project No. 00508103, Approval No. EU 1/95/002/002
84. Kudoh S, Negoro S, Masuda N, Sugiura T, Saka H, Fukuoka M: Phase I/II study of docetaxel and irinotecan for previously untreated advanced non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 17: A1891, 1998
85. Hennequin C, Giocanti N, Favaudon V: Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 56: 1842-1850, 1996
86. Yokes EE, Masters GA, Mauer A, Haraf DJ, Hoffman PC, Golomb HM: Clinical studies of docetaxel and concomittant chest therapy. Semin Oncol 24 (Suppl 14): S14-26-S14-29, 1997
87. Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Yokes EE: Phase I study of docetaxel with concomittant thoracic radiation therapy. J Clin Oncol 16(1): 159-164, 1998
88. Masters GA, Haraf DJ, Hoffman PC, et al: Phase I study of concomitant docetaxel (Taxotere) and radiation in advanced chest malignancies (abstract 1112). Proc Am Soc Clin Oncol 15: 314, 1996
89. Koukourakis M, Giatromanolaki A, Schiza S, Kakolyris S, Georgoulias V. Concurrent twice-a-week docetaxel and radiotherapy: A dose escalation trial with immunologic toxicity evaluation. Int J Radiat Oncol Biol Phys 43 (Suppl 1): 107-114, 1999
90. Koukourakis MI, Kourousis C, Kamilaki M, Koukouraki S, Giatromanolaki A, Kakolyris S, Kotsakis A, Androulakis N, Bahlitzanakis N, Georgoulias V: Weekly docetaxel and concomittant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer 34(6): 838-844, 1998
91. Aamdal S, Hallén MN, Tonelli D, Lauvvang G, Cure K, Hatlevoll R: Phase I/II study of Docetaxel (Taxotere) combined with radiation in locally advanced non-small cell lung cancer (abstract A-1830). Proc Am Soc Clin Oncol 17: 476a; A1830, 1998
92. Teng M, Choy H, DeVore D, Hande KR, Arteaga CL, Porter LL, Rosenblatt PA, Slovis B, Laporte K, Shry Y, Johnson DA: Phase I trial of outpatient weekly docetaxel and concurrent radiation therapy for stage III unresectable non-small cell lung cancer. Vanderbilt Cancer Center Affiliate Network (VCCAN) trial (abstract). Proc Am Soc Clin Oncol 17: A1938, 1998
93. Gob BC, Wang TL, Wong J, Lin HL, Lin J, Kong HL, Lee SC: Phase II trial of docetaxel in inoperable stage in non-small cell lung cancer (abstract). Proc Am Soc Clin Oncol 16: A1686, 1997
94. Mattson K, Ten Velde G, Krofta K, Eggleton SPH, LeMoigne A, Harper P: Taxotere as neoadjuvant therapy for radically treatable stage In NSCLC: preliminary results of an international study. Proc Am Soc Clin Oncol 17: A-1904, 1998
95. Herse B, Dalichau H, Wormann B, Hemmerlein B, Schmidberger H, Hess CF, Hannemann P, Criee CP, Hiddemann W, Griesinger F. Induction combination chemotherapy with docetaxel and carboplatin in advanced non-small cell lung cancer. Thorac Cardiovasc Surg 46 (Suppl 5): 298-302, 1998
96. Smyth JF, Smith IE, Sessa C, et al: Activity of docetaxel in small cell lung cancer. Fur J Cancer 30A(8): 1058-1060, 1994
97. Latreille J, Cormier Y, Martins H, Gross G, Fisher B, Eisenhauer EA: Phase II study of docetaxel in patients with previously untreated extensive small cell lung cancer. Invest New Drugs 13(4): 343-345, 1996
98. Hesketh PJ, Crowley JJ, Burris HA, et al: Evaluation of docetaxel in previously untreated extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial, submitted to ASCO.